维普期刊资源整合服务平台（V6.5）

21篇 您的检索式：作者名="Sehestedt"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score 显示文摘	Lyngb~ek S Marott J L Sehestedt T	2013	International journal of cardiology2013，167，6：	1
2	Risk prediction is im- proved by adding markers of subclinical organ damage to SCORE 显示文摘	Sehestedt T Jeppesen J Hansen TW	2010	Eur Heart J2010，31，7：	1
3	Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population显示文摘	Sehestedt T Jeppesen J Hansen TW	2009	J Hypertens2009，27，12：	1
4	Risk prediction is improved by adding markers of subclinical organ damage to SCORE显示文摘	Sehestedt T Jeppesen J Hansen TW	2010	Eur Heart J2010，31，7：	1
5	Iodine intake and incidence of thyroid cancer in Denmark显示文摘	Sehestedt T Knudsen N Perrild H	2006	Clin Endocrinol2006，65，：	1
6	Risk prediction is improved by adding markers of subclinical organ damage to SCORE显示文摘	Sehestedt T Jeppesen J Hansen TW	2010	Eur Heart J2010，31，7：	1
7	Which markers of subclinical organ damage to measure in individuals with high normal blood pressure?显示文摘	Sehestedt T Jeppesen J Hansen TW	2009	J Hypertens2009，27，6：	1
8	Effective risk stratification in patients with moderate cardiovascu- lar risk using albuminuria and atherosclerotic plaques in the carotid arteries 显示文摘	Greve S V Blicher M K Sehestedt T	2015	J Hypertens2015，33，8：	1
9	Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients:the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study显示文摘	Ruwald AC Westergaard B Sehestedt T	2012	J Hypertens2012，30，6：	1
10	Losartan versusatenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients:the losartan intervention for endpoint reduction in hypertension (LIFE)study显示文摘	Ruwald AC Westergaard B Sehestedt T		0，，06：	1
11	Cardiovascular risk predic- tion in the general population with use of suPAR, CRP, and Fram- ingham Risk Score 显示文摘	Lyngbek S Marott JL Sehestedt T	2013	Int J Cardiol2013，167，6：	1
12	Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population 显示文摘	Sehestedt T Jeppesen J Hansen TW	2009	J Hypertens2009，27，12：	1
13	Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score显示文摘	Lyngbmk S Marott JL Sehestedt T	2013	Int J Cardiol2013，167，6：	1
14	Risk stratification with the risk chart from the European Soci- ety of Hypertension compared with SCORE in the gen- eralpopulation显示文摘	T Sehestedt J Jeppesen TW Hansen	2009	Hypertens2009，27，12：	1
15	Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events显示文摘	Sehestedt S Lyngb K J Eugen-Olsen J	2011	Atherosclerosis2011，216，1：	1
16	Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events显示文摘	Sehestedt T Lyngbaek S Eugen-Olsen J	2011	Atherosclerosis2011，216，1：	1
17	Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the losartan intervention for endpoint reduction in hypertension (LIFE) study显示文摘	Ruwald AC Westergaard B Sehestedt T	2012	J Hypertens2012，30，6：	1
18	Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population 显示文摘	SEHESTEDT T JEPPESEN J HANSEN T W	2009	Hypertens2009，27，12：	1
19	Risk prediction is improved by adding markers of subclinical organ damage to SCORE显示文摘	SEHESTEDT T JEPPESEN J HANSEN T W	2010	Eur Heart2010，31，：	1
20	Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts显示文摘	Sehestedt T Jeppesen J Hansen TW	2012	J Hypertens2012，30，：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示